Sanofi Settles With Teva, Others Over Generic Eloxatin
Law360 (April 1, 2010, 5:40 PM EDT) -- Sanofi-Aventis SA has settled patent litigation against three drugmakers — Teva Pharmaceuticals Inc., Fresenius Kabi Pharmaceuticals Holding Inc. and Sandoz Inc. — over their plans to sell generic versions of cancer drug Eloxatin.
The deal, announced Thursday, resolves Sanofi's claims against the three in suits in the U.S. District Court for the District of New Jersey and the U.S. District Court for the District of Columbia, and will see generic versions of drug the pulled from the market within a few months.
The U.S. Food and Drug Administration allowed Teva to begin marketing its versions of Eloxatin, also known as oxaliplatin,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!